Method for treating bone related diseases and calcium disorders
View Patent ↗Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin.
1. A method for treating bone related diseases and calcium disorders, said method comprising: administering to a patient in need of such treatment a pharmaceutical composition comprising:
a. a therapeutically effective amount of calcitonin
b. a pharmaceutically acceptable inactive excipient, and
c. a delivery agent of formula I for said calcitonin
wherein
R 1 , R 2 , R 3 , and R 4 are independently hydrogen, —OH, —NR 6 R 7 , halogen, C 1 -C 4 alkyl, or C 1 -C 4 alkoxy;
R 5 is a substituted or unsubstituted C 2 -C 16 alkylene, substituted or unsubstituted C 2 -C 16 alkenylene, substituted or unsubstituted C 1 -C 12 alkyl(arylene), or substituted or unsubstituted aryl(C 1 -C 4 alkylene); and
R 6 and R 7 are independently hydrogen, oxygen, or C 1 -C 4 alkyl; and hydrates, pharmaceutically acceptable salts and solvates thereof, wherein said delivery agent is in micronized form and has an average particle size of less than 10 microns.
2. The method of claim 1 wherein the calcitonin is salmon calcitonin.
3. The method of claim 1 wherein said inactive excipient is selected from the group consisting of crospovidone and povidone.
4. The method of claim 1 , wherein the delivery agent is selected from the group consisting of N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), N-(10-[2-hydroxybenzoly]amino)decanoic acid (SNAD), N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC) and disodium salts thereof.
5. The method according to claim 4 , wherein the delivery agent is selected from the group consisting of a disodium salt of 5-CNAC, a disodium salt of SNAD, and a disodium salt of SNAC.
6. The method of claim 1 wherein the pharmaceutical composition further comprises a diluent.
7. The method of claim 6 wherein the diluent is microcrystalline cellulose.
8. The method of claim 1 wherein the pharmaceutical composition further comprises a lubricant.
9. The method of claim 8 wherein the lubricant is magnesium stearate.
10. The method of claim 5 , wherein the delivery agent is the disodium salt of 5-CNAC.